Alliance Pharma announces Kristof Neirynck to its Board as upcoming Independent Director

– UK, Chippenham –  Alliance Pharma plc (LON: APH), the international healthcare group, today announced the appointment of highly experienced consumer brands executive, Kristof Neirynck, to its Board as an Independent Non-Executive Director, effective on 1 December 2021, bringing the number of independent Directors to four.

“I am delighted to confirm the appointment of Kristof as a Non-Executive Director of Alliance and we look forward to his joining the Group on 1 December this year. Kristof brings outstanding operational and strategic experience of the consumer healthcare market, gained at global businesses. His international, omni-channel and marketing experience is highly complementary to the skillset of the existing Board members as we focus on the Group’s international expansion.” said Board Chairman, David Cook.

About Kristof Neirynck

Kristof is currently Group VP and Chief Marketing Officer Global Brands at Walgreens-Boots-Alliance, a global leader in retail pharmacy. He brings almost 20 years of international consumer brand experience including complex omnichannel business models, direct-to-consumer strategies and cross border e-commerce into China.

Kristof started his career in 2002 at Procter & Gamble in Belgium before moving to Procter & Gamble International in Switzerland in 2004 and working there for 11 years. He joined WBA in 2015 as VP & Global Category Director Skin Care before being appointed to his current role in 2017. In this role, he has global responsibility for the portfolio of more than 20 WBA-owned brands across Beauty and Consumer Healthcare, representing more than $4bn in sales.

About Alliance

Alliance Pharma plc is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.